Last verified: March 2026

CBD Market Overview

Japan's CBD market is one of the largest in Asia and has experienced explosive growth. Between 2019 and 2020 alone, the market grew by 171%, driven by wellness-conscious consumers seeking alternatives to traditional pharmaceuticals. By 2023, the market was estimated at over $160 million, with more than 150 companies offering CBD oils, tinctures, edibles, beverages, skincare products, and vape liquids.

CBD products are sold in pharmacies, convenience stores, dedicated CBD shops, and extensively online. Major Japanese retailers have stocked CBD products, and the market has attracted both domestic startups and international brands seeking access to Japan's affluent consumer base.

Legal Framework

CBD itself is not a controlled substance in Japan. However, the legal framework governing CBD products is complex and has become significantly more restrictive following the 2024 law reform.

Source Restriction: Stalks and Seeds Only

Japan's original Cannabis Control Act (1948) excluded the mature stalks and seeds of the cannabis plant from the definition of "cannabis." This means CBD products sold in Japan must theoretically be derived exclusively from these plant parts — not from flowers, leaves, or resin, which remain classified as cannabis.

In practice, this is a significant constraint. The highest concentration of CBD in the cannabis plant is found in the flowers and leaves, not the stalks or seeds. Products sourced from compliant plant parts tend to have lower CBD concentrations and require more extensive processing.

New THC Residue Limits (Effective December 12, 2024)

The most impactful change for the CBD industry is the introduction of specific maximum THC residue limits. Prior to the reform, there were no quantified limits — the standard was simply that products must contain no THC from prohibited plant parts. The new limits are:

How Japan Compares Internationally

Japan's THC limits are extraordinarily strict compared to global standards:

Japan's oil limit of 10 ppm is 300 times stricter than the US threshold. The beverage limit of 0.1 ppm is 30,000 times stricter. Only South Korea's zero-tolerance approach is more restrictive.

ISO 17025 Testing Requirements

All CBD products must now be tested by laboratories holding ISO 17025 accreditation — the international standard for testing and calibration laboratories. This is the same accreditation required for pharmaceutical-grade testing. Products must include testing documentation verifying THC levels fall within the permitted limits.

Labeling Requirements

CBD products sold in Japan must include clear labeling showing:

• CBD content per unit and per serving
• Source plant parts (must indicate stalks/seeds derivation)
• Country of origin
• Importer or distributor information
• THC testing certification from an accredited laboratory
• No medical claims (CBD products cannot claim to treat, cure, or prevent any disease)

Impact of New Limits on the CBD Market

The new THC residue limits are expected to fundamentally reshape Japan's CBD industry. Industry analysts and trade groups have estimated that the impact will be severe:

An Estimated 90% of Products May Fail

Most CBD products currently sold in Japan — particularly those using broad-spectrum or full-spectrum extracts — contain THC levels well above the new limits. Industry estimates suggest that 90% or more of products currently on the market would fail the new THC testing requirements. Even products marketed as "THC-free" often contain trace amounts that exceed 10 ppm when tested with the sensitivity required by ISO 17025 methods.

Shift to CBD Isolate

The most practical way for companies to meet the new limits is to switch to CBD isolate — pure crystalline CBD with 99%+ purity and virtually zero THC. This eliminates the risk of THC contamination but also eliminates the other cannabinoids and terpenes present in full-spectrum products, which some consumers and researchers believe contribute to therapeutic effects (the "entourage effect").

Market Consolidation

Smaller CBD companies without the resources to invest in ISO 17025 testing, reformulation, and compliance infrastructure are likely to exit the market. The industry is expected to consolidate around larger, better-funded companies that can absorb the compliance costs. This may also benefit established pharmaceutical and supplement companies entering the CBD space with existing quality assurance infrastructure.

The new regulatory framework for CBD products, including THC residue limits and mandatory ISO 17025 laboratory testing, took effect with the enforcement of the amended Cannabis and Psychotropic Substances Control Act.

MHLW — CBD Product Regulatory Guidance, 2024

Buying CBD in Japan: Practical Guidance

• Purchase from established retailers. Major pharmacies and well-known online retailers are most likely to carry compliant products.
• Check for testing documentation. Look for products that include ISO 17025 test results or certificates of analysis (COAs) from accredited laboratories.
• Avoid imports. CBD products purchased abroad may not meet Japan's strict THC limits and could be seized at customs or, worse, treated as narcotics importation.
• Be skeptical of claims. Any CBD product claiming to cure or treat medical conditions is violating Japanese pharmaceutical advertising law.